4.8 Article

Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

Journal

CELL REPORTS
Volume 31, Issue 5, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2020.107550

Keywords

-

Categories

Funding

  1. Renal and Skin Unit Research Team
  2. Roche Tissue Diagnostics - Medical Research Council [MR/P014712/1]
  3. Rosetrees Trust [A2204]
  4. Cancer Research UK
  5. CRUK Lung Cancer Centre of Excellence - Fondation de France
  6. Royal Society Napier Research Professor
  7. Francis Crick Institute
  8. Medical Research Council [FC001169]
  9. Wellcome Trust [FC001169]
  10. (CRUK Cancer Immunotherapy Catalyst Network)
  11. CRUK Lung Cancer Centre of Excellence
  12. NovoNordisk Foundation [ID16584]
  13. Breast Cancer Research Foundation (BCRF)
  14. Stand Up To Cancer (SU2C)-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2C-AACR-DT23-17]
  15. scientific partner of SU2C
  16. European Research Council (ERC) under the European Union [FP7-THESEUS-617844]
  17. European Commission ITN [607722]
  18. ERC Advanced Grant (PROTEUS) from the ERC under the European Union [835297]
  19. European Union [665233]
  20. National Institute for Health Research (NIHR) RM/ICR Biomedical Research Centre for Cancer - Cancer Research UK [C50947/A18176]
  21. NIHR Biomedical Research Centre at the Royal Marsden Hospital [A109]
  22. Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity
  23. Ventana Medical Systems Inc. [10467, 10530]
  24. MRC [MR/P014712/1] Funding Source: UKRI
  25. European Research Council (ERC) [835297] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which becomes grossly under-powered as tumor volume scales. Here, we demonstrate representative sequencing (Rep-Seq) as a new method to achieve unbiased tumor tissue sampling. Rep-Seq uses fixed residual tumor material, which is homogenized and subjected to next-generation sequencing. Analysis of intratumor tumor mutation burden (TMB) variability shows a high level of misclassification using current single-biopsy methods, with 20% of lung and 52% of bladder tumors having at least one biopsy with high TMB but low clonal TMB overall. Misclassification rates by contrast are reduced to 2% (lung) and 4% (bladder) when a more representative sampling methodology is used. Rep-Seq offers an improved sampling protocol for tumor profiling, with significant potential for improved clinical utility and more accurate deconvolution of clonal structure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available